Global Swine Mycoplasma Hyopneumoniae Vaccine Market Growth 2026-2032
The global Swine Mycoplasma Hyopneumoniae Vaccine market size is predicted to grow from US$ 709 million in 2025 to US$ 998 million in 2032; it is expected to grow at a CAGR of 5.0% from 2026 to 2032.
Swine Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product used to prevent and control respiratory disease associated with Mycoplasma hyopneumoniae infection in pigs. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of swine enzootic pneumonia, coughing, lung lesions, secondary infections and production performance losses. The product category includes inactivated vaccines, live attenuated vaccines, subunit or recombinant vaccines, and dual or multivalent vaccines containing Mycoplasma hyopneumoniae antigen together with antigens such as porcine circovirus type 2. Inactivated vaccines and combination vaccines containing Mycoplasma hyopneumoniae antigen remain the mainstream product forms globally, while live vaccines are mainly used in China and a limited number of regional markets. Key upstream materials include production strains, dedicated culture media, inactivating agents, attenuated-strain culture materials, recombinant antigen expression materials, adjuvants, buffers, stabilizers, freeze-drying protectants, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. The global effective capacity of this product category is estimated at around 1.58 billion doses in 2025, with sales volume of approximately 1.246 billion doses and an average ex-factory price of about USD 0.58 per dose. The industry gross margin in 2025 is estimated at roughly 46%?66%, with multinational brands, dual vaccines, multivalent vaccines and one-shot immunization products usually positioned at the upper end of the range, while local single vaccines and regional products are more commonly positioned in the middle to lower part of the range.
The Swine Mycoplasma Hyopneumoniae Vaccine market has established a mature global application base, with demand mainly supported by the long-term need for respiratory disease control in large-scale swine farms. As pig production continues to move toward group-based, intensive and refined management, producers are placing greater emphasis on stable vaccination programs, herd uniformity, feed conversion improvement and control of secondary infections. These vaccines are widely used in piglet and nursery-stage immunization and have become an important part of basic herd health programs. Current competition is no longer limited to price, but is increasingly shaped by immune efficacy stability, product safety, farm-level technical service capability and the value of integrated disease-control solutions.
Looking ahead, the market will continue to upgrade toward combination vaccines, one-shot immunization and scenario-based vaccination programs, especially products linked with the prevention of porcine circovirus type 2 and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. Adjuvant systems, antigen purification, strain adaptability, recombinant antigen expression and batch-to-batch consistency will become key directions for product upgrading. Industry competition will gradually shift from traditional single-vaccine competition toward high-quality combination vaccines, differentiated strains and integrated immunization solutions.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, it has a long-term impact on feed conversion, average daily gain, lung lesions and secondary infections, creating hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, batch consistency and whole-cycle herd health value. Companies with stable supply capacity, strong product portfolios and farm service systems are more likely to gain recognition from large-scale customers.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of new vaccine routes may also limit market penetration. Meanwhile, differences in local epidemic strains, regulatory approval requirements, cold-chain distribution conditions and efficacy comparison among different technology routes add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
LP Information, Inc. (LPI) ' newest research report, the ?Swine Mycoplasma Hyopneumoniae Vaccine Industry Forecast? looks at past sales and reviews total world Swine Mycoplasma Hyopneumoniae Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Mycoplasma Hyopneumoniae Vaccine sales for 2026 through 2032. With Swine Mycoplasma Hyopneumoniae Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Mycoplasma Hyopneumoniae Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Mycoplasma Hyopneumoniae Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Mycoplasma Hyopneumoniae Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Swine Mycoplasma Hyopneumoniae Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Mycoplasma Hyopneumoniae Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Mycoplasma Hyopneumoniae Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Mycoplasma Hyopneumoniae Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Swine Mycoplasma Hyopneumoniae Vaccine market?
What factors are driving Swine Mycoplasma Hyopneumoniae Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Mycoplasma Hyopneumoniae Vaccine market opportunities vary by end market size?
How does Swine Mycoplasma Hyopneumoniae Vaccine break out by Type, by Application?
Swine Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product used to prevent and control respiratory disease associated with Mycoplasma hyopneumoniae infection in pigs. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of swine enzootic pneumonia, coughing, lung lesions, secondary infections and production performance losses. The product category includes inactivated vaccines, live attenuated vaccines, subunit or recombinant vaccines, and dual or multivalent vaccines containing Mycoplasma hyopneumoniae antigen together with antigens such as porcine circovirus type 2. Inactivated vaccines and combination vaccines containing Mycoplasma hyopneumoniae antigen remain the mainstream product forms globally, while live vaccines are mainly used in China and a limited number of regional markets. Key upstream materials include production strains, dedicated culture media, inactivating agents, attenuated-strain culture materials, recombinant antigen expression materials, adjuvants, buffers, stabilizers, freeze-drying protectants, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. The global effective capacity of this product category is estimated at around 1.58 billion doses in 2025, with sales volume of approximately 1.246 billion doses and an average ex-factory price of about USD 0.58 per dose. The industry gross margin in 2025 is estimated at roughly 46%?66%, with multinational brands, dual vaccines, multivalent vaccines and one-shot immunization products usually positioned at the upper end of the range, while local single vaccines and regional products are more commonly positioned in the middle to lower part of the range.
The Swine Mycoplasma Hyopneumoniae Vaccine market has established a mature global application base, with demand mainly supported by the long-term need for respiratory disease control in large-scale swine farms. As pig production continues to move toward group-based, intensive and refined management, producers are placing greater emphasis on stable vaccination programs, herd uniformity, feed conversion improvement and control of secondary infections. These vaccines are widely used in piglet and nursery-stage immunization and have become an important part of basic herd health programs. Current competition is no longer limited to price, but is increasingly shaped by immune efficacy stability, product safety, farm-level technical service capability and the value of integrated disease-control solutions.
Looking ahead, the market will continue to upgrade toward combination vaccines, one-shot immunization and scenario-based vaccination programs, especially products linked with the prevention of porcine circovirus type 2 and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. Adjuvant systems, antigen purification, strain adaptability, recombinant antigen expression and batch-to-batch consistency will become key directions for product upgrading. Industry competition will gradually shift from traditional single-vaccine competition toward high-quality combination vaccines, differentiated strains and integrated immunization solutions.
The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although Mycoplasma hyopneumoniae infection is usually not characterized by acute high mortality, it has a long-term impact on feed conversion, average daily gain, lung lesions and secondary infections, creating hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, batch consistency and whole-cycle herd health value. Companies with stable supply capacity, strong product portfolios and farm service systems are more likely to gain recognition from large-scale customers.
Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of new vaccine routes may also limit market penetration. Meanwhile, differences in local epidemic strains, regulatory approval requirements, cold-chain distribution conditions and efficacy comparison among different technology routes add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.
LP Information, Inc. (LPI) ' newest research report, the ?Swine Mycoplasma Hyopneumoniae Vaccine Industry Forecast? looks at past sales and reviews total world Swine Mycoplasma Hyopneumoniae Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Mycoplasma Hyopneumoniae Vaccine sales for 2026 through 2032. With Swine Mycoplasma Hyopneumoniae Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Swine Mycoplasma Hyopneumoniae Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Swine Mycoplasma Hyopneumoniae Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Mycoplasma Hyopneumoniae Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Swine Mycoplasma Hyopneumoniae Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Mycoplasma Hyopneumoniae Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Mycoplasma Hyopneumoniae Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Swine Mycoplasma Hyopneumoniae Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Inactivated Vaccine
- Live Attenuated Vaccine
- Others
- Single Vaccine
- Dual Vaccine
- Others
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20?50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Pig Farming Groups
- Breeding Pig Farms
- Veterinary Service Providers
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Zoetis
- Boehringer Ingelheim
- Merck Animal Health
- Ceva Sant? Animale
- HIPRA
- Bioveta
- Vaxxinova
- Nisseiken
- Kyoto Biken Laboratories
- Pulike Biological Engineering
- Wuhan Keqian Biology
- Qilu Animal Health
- Huapai Biotechnology
- TianKang Pharmaceutical
- Jinyu Bio-technology
- Zhaofenghua Bio-technology
- Yunnan Biopharmaceutical
- Yangzhou Uni-Bio Pharmaceutical
What is the 10-year outlook for the global Swine Mycoplasma Hyopneumoniae Vaccine market?
What factors are driving Swine Mycoplasma Hyopneumoniae Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Swine Mycoplasma Hyopneumoniae Vaccine market opportunities vary by end market size?
How does Swine Mycoplasma Hyopneumoniae Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Type
2.2.1 Inactivated Vaccine
2.2.2 Live Attenuated Vaccine
2.2.3 Others
2.2.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type
2.2.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026)
2.3 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Vaccine Valency
2.3.1 Single Vaccine
2.3.2 Dual Vaccine
2.3.3 Others
2.3.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency
2.3.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)
2.3.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Vaccine Valency (2021-2026)
2.3.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026)
2.4 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size
2.4.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Application
2.5.1 Large-scale Pig Farming Groups
2.5.2 Breeding Pig Farms
2.5.3 Veterinary Service Providers
2.5.4 Others
2.5.5 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application
2.5.5.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Breakdown Data by Company
3.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026)
3.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Product Location Distribution
3.4.2 Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.4 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.5 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
5 AMERICAS
5.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country
5.1.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
5.1.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
5.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
5.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region
6.1.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026)
6.1.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026)
6.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
6.3 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine by Country
7.1.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
7.1.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
7.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
7.3 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine by Country
8.1.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
10.3 Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
10.4 Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Mycoplasma Hyopneumoniae Vaccine Distributors
11.3 Swine Mycoplasma Hyopneumoniae Vaccine Customer
12 WORLD FORECAST REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION
12.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Market Size Forecast by Region
12.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Region (2027-2032)
12.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Type (2027-2032)
12.7 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Zoetis
13.1.1 Zoetis Company Information
13.1.2 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.1.3 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Zoetis Main Business Overview
13.1.5 Zoetis Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Merck Animal Health
13.3.1 Merck Animal Health Company Information
13.3.2 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.3.3 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Animal Health Main Business Overview
13.3.5 Merck Animal Health Latest Developments
13.4 Ceva Sant? Animale
13.4.1 Ceva Sant? Animale Company Information
13.4.2 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.4.3 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ceva Sant? Animale Main Business Overview
13.4.5 Ceva Sant? Animale Latest Developments
13.5 HIPRA
13.5.1 HIPRA Company Information
13.5.2 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.5.3 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 HIPRA Main Business Overview
13.5.5 HIPRA Latest Developments
13.6 Bioveta
13.6.1 Bioveta Company Information
13.6.2 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.6.3 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bioveta Main Business Overview
13.6.5 Bioveta Latest Developments
13.7 Vaxxinova
13.7.1 Vaxxinova Company Information
13.7.2 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.7.3 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Vaxxinova Main Business Overview
13.7.5 Vaxxinova Latest Developments
13.8 Nisseiken
13.8.1 Nisseiken Company Information
13.8.2 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.8.3 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nisseiken Main Business Overview
13.8.5 Nisseiken Latest Developments
13.9 Kyoto Biken Laboratories
13.9.1 Kyoto Biken Laboratories Company Information
13.9.2 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.9.3 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Kyoto Biken Laboratories Main Business Overview
13.9.5 Kyoto Biken Laboratories Latest Developments
13.10 Pulike Biological Engineering
13.10.1 Pulike Biological Engineering Company Information
13.10.2 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.10.3 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Pulike Biological Engineering Main Business Overview
13.10.5 Pulike Biological Engineering Latest Developments
13.11 Wuhan Keqian Biology
13.11.1 Wuhan Keqian Biology Company Information
13.11.2 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.11.3 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Wuhan Keqian Biology Main Business Overview
13.11.5 Wuhan Keqian Biology Latest Developments
13.12 Qilu Animal Health
13.12.1 Qilu Animal Health Company Information
13.12.2 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.12.3 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Qilu Animal Health Main Business Overview
13.12.5 Qilu Animal Health Latest Developments
13.13 Huapai Biotechnology
13.13.1 Huapai Biotechnology Company Information
13.13.2 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.13.3 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Huapai Biotechnology Main Business Overview
13.13.5 Huapai Biotechnology Latest Developments
13.14 TianKang Pharmaceutical
13.14.1 TianKang Pharmaceutical Company Information
13.14.2 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.14.3 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 TianKang Pharmaceutical Main Business Overview
13.14.5 TianKang Pharmaceutical Latest Developments
13.15 Jinyu Bio-technology
13.15.1 Jinyu Bio-technology Company Information
13.15.2 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.15.3 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Jinyu Bio-technology Main Business Overview
13.15.5 Jinyu Bio-technology Latest Developments
13.16 Zhaofenghua Bio-technology
13.16.1 Zhaofenghua Bio-technology Company Information
13.16.2 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.16.3 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhaofenghua Bio-technology Main Business Overview
13.16.5 Zhaofenghua Bio-technology Latest Developments
13.17 Yunnan Biopharmaceutical
13.17.1 Yunnan Biopharmaceutical Company Information
13.17.2 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.17.3 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Yunnan Biopharmaceutical Main Business Overview
13.17.5 Yunnan Biopharmaceutical Latest Developments
13.18 Yangzhou Uni-Bio Pharmaceutical
13.18.1 Yangzhou Uni-Bio Pharmaceutical Company Information
13.18.2 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.18.3 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Yangzhou Uni-Bio Pharmaceutical Main Business Overview
13.18.5 Yangzhou Uni-Bio Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Type
2.2.1 Inactivated Vaccine
2.2.2 Live Attenuated Vaccine
2.2.3 Others
2.2.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type
2.2.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026)
2.3 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Vaccine Valency
2.3.1 Single Vaccine
2.3.2 Dual Vaccine
2.3.3 Others
2.3.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency
2.3.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)
2.3.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Vaccine Valency (2021-2026)
2.3.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026)
2.4 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size
2.4.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Application
2.5.1 Large-scale Pig Farming Groups
2.5.2 Breeding Pig Farms
2.5.3 Veterinary Service Providers
2.5.4 Others
2.5.5 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application
2.5.5.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Breakdown Data by Company
3.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026)
3.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company
3.4 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Product Location Distribution
3.4.2 Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.4 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.5 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth
5 AMERICAS
5.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country
5.1.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
5.1.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
5.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
5.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region
6.1.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026)
6.1.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026)
6.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
6.3 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine by Country
7.1.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
7.1.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
7.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
7.3 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine by Country
8.1.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
10.3 Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
10.4 Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Swine Mycoplasma Hyopneumoniae Vaccine Distributors
11.3 Swine Mycoplasma Hyopneumoniae Vaccine Customer
12 WORLD FORECAST REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION
12.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Market Size Forecast by Region
12.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Region (2027-2032)
12.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Type (2027-2032)
12.7 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Zoetis
13.1.1 Zoetis Company Information
13.1.2 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.1.3 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Zoetis Main Business Overview
13.1.5 Zoetis Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 Merck Animal Health
13.3.1 Merck Animal Health Company Information
13.3.2 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.3.3 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Animal Health Main Business Overview
13.3.5 Merck Animal Health Latest Developments
13.4 Ceva Sant? Animale
13.4.1 Ceva Sant? Animale Company Information
13.4.2 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.4.3 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ceva Sant? Animale Main Business Overview
13.4.5 Ceva Sant? Animale Latest Developments
13.5 HIPRA
13.5.1 HIPRA Company Information
13.5.2 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.5.3 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 HIPRA Main Business Overview
13.5.5 HIPRA Latest Developments
13.6 Bioveta
13.6.1 Bioveta Company Information
13.6.2 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.6.3 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bioveta Main Business Overview
13.6.5 Bioveta Latest Developments
13.7 Vaxxinova
13.7.1 Vaxxinova Company Information
13.7.2 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.7.3 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Vaxxinova Main Business Overview
13.7.5 Vaxxinova Latest Developments
13.8 Nisseiken
13.8.1 Nisseiken Company Information
13.8.2 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.8.3 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nisseiken Main Business Overview
13.8.5 Nisseiken Latest Developments
13.9 Kyoto Biken Laboratories
13.9.1 Kyoto Biken Laboratories Company Information
13.9.2 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.9.3 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Kyoto Biken Laboratories Main Business Overview
13.9.5 Kyoto Biken Laboratories Latest Developments
13.10 Pulike Biological Engineering
13.10.1 Pulike Biological Engineering Company Information
13.10.2 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.10.3 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Pulike Biological Engineering Main Business Overview
13.10.5 Pulike Biological Engineering Latest Developments
13.11 Wuhan Keqian Biology
13.11.1 Wuhan Keqian Biology Company Information
13.11.2 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.11.3 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Wuhan Keqian Biology Main Business Overview
13.11.5 Wuhan Keqian Biology Latest Developments
13.12 Qilu Animal Health
13.12.1 Qilu Animal Health Company Information
13.12.2 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.12.3 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Qilu Animal Health Main Business Overview
13.12.5 Qilu Animal Health Latest Developments
13.13 Huapai Biotechnology
13.13.1 Huapai Biotechnology Company Information
13.13.2 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.13.3 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Huapai Biotechnology Main Business Overview
13.13.5 Huapai Biotechnology Latest Developments
13.14 TianKang Pharmaceutical
13.14.1 TianKang Pharmaceutical Company Information
13.14.2 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.14.3 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 TianKang Pharmaceutical Main Business Overview
13.14.5 TianKang Pharmaceutical Latest Developments
13.15 Jinyu Bio-technology
13.15.1 Jinyu Bio-technology Company Information
13.15.2 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.15.3 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Jinyu Bio-technology Main Business Overview
13.15.5 Jinyu Bio-technology Latest Developments
13.16 Zhaofenghua Bio-technology
13.16.1 Zhaofenghua Bio-technology Company Information
13.16.2 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.16.3 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhaofenghua Bio-technology Main Business Overview
13.16.5 Zhaofenghua Bio-technology Latest Developments
13.17 Yunnan Biopharmaceutical
13.17.1 Yunnan Biopharmaceutical Company Information
13.17.2 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.17.3 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Yunnan Biopharmaceutical Main Business Overview
13.17.5 Yunnan Biopharmaceutical Latest Developments
13.18 Yangzhou Uni-Bio Pharmaceutical
13.18.1 Yangzhou Uni-Bio Pharmaceutical Company Information
13.18.2 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
13.18.3 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Yangzhou Uni-Bio Pharmaceutical Main Business Overview
13.18.5 Yangzhou Uni-Bio Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inactivated Vaccine
Table 4. Major Players of Live Attenuated Vaccine
Table 5. Major Players of Others
Table 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Single Vaccine
Table 12. Major Players of Dual Vaccine
Table 13. Major Players of Others
Table 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency (2021-2026) & (K Dose)
Table 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)
Table 16. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Vaccine Valency (2021-2026) & ($ million)
Table 17. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
Table 18. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution and Sales Area
Table 38. Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered
Table 39. Swine Mycoplasma Hyopneumoniae Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Swine Mycoplasma Hyopneumoniae Vaccine
Table 69. Key Market Challenges & Risks of Swine Mycoplasma Hyopneumoniae Vaccine
Table 70. Key Industry Trends of Swine Mycoplasma Hyopneumoniae Vaccine
Table 71. Swine Mycoplasma Hyopneumoniae Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Swine Mycoplasma Hyopneumoniae Vaccine Distributors List
Table 74. Swine Mycoplasma Hyopneumoniae Vaccine Customer List
Table 75. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Zoetis Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 91. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Zoetis Main Business
Table 93. Zoetis Latest Developments
Table 94. Boehringer Ingelheim Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 96. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Boehringer Ingelheim Main Business
Table 98. Boehringer Ingelheim Latest Developments
Table 99. Merck Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 101. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Merck Animal Health Main Business
Table 103. Merck Animal Health Latest Developments
Table 104. Ceva Sant? Animale Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 106. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Ceva Sant? Animale Main Business
Table 108. Ceva Sant? Animale Latest Developments
Table 109. HIPRA Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 111. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. HIPRA Main Business
Table 113. HIPRA Latest Developments
Table 114. Bioveta Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 116. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Bioveta Main Business
Table 118. Bioveta Latest Developments
Table 119. Vaxxinova Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 121. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Vaxxinova Main Business
Table 123. Vaxxinova Latest Developments
Table 124. Nisseiken Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 126. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Nisseiken Main Business
Table 128. Nisseiken Latest Developments
Table 129. Kyoto Biken Laboratories Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 131. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Kyoto Biken Laboratories Main Business
Table 133. Kyoto Biken Laboratories Latest Developments
Table 134. Pulike Biological Engineering Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 136. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Pulike Biological Engineering Main Business
Table 138. Pulike Biological Engineering Latest Developments
Table 139. Wuhan Keqian Biology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 141. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Wuhan Keqian Biology Main Business
Table 143. Wuhan Keqian Biology Latest Developments
Table 144. Qilu Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 146. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Qilu Animal Health Main Business
Table 148. Qilu Animal Health Latest Developments
Table 149. Huapai Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 151. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Huapai Biotechnology Main Business
Table 153. Huapai Biotechnology Latest Developments
Table 154. TianKang Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 156. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. TianKang Pharmaceutical Main Business
Table 158. TianKang Pharmaceutical Latest Developments
Table 159. Jinyu Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 160. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 161. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. Jinyu Bio-technology Main Business
Table 163. Jinyu Bio-technology Latest Developments
Table 164. Zhaofenghua Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 165. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 166. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Zhaofenghua Bio-technology Main Business
Table 168. Zhaofenghua Bio-technology Latest Developments
Table 169. Yunnan Biopharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 170. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 171. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Yunnan Biopharmaceutical Main Business
Table 173. Yunnan Biopharmaceutical Latest Developments
Table 174. Yangzhou Uni-Bio Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 175. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 176. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Yangzhou Uni-Bio Pharmaceutical Main Business
Table 178. Yangzhou Uni-Bio Pharmaceutical Latest Developments
Table 1. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inactivated Vaccine
Table 4. Major Players of Live Attenuated Vaccine
Table 5. Major Players of Others
Table 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Single Vaccine
Table 12. Major Players of Dual Vaccine
Table 13. Major Players of Others
Table 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency (2021-2026) & (K Dose)
Table 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)
Table 16. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Vaccine Valency (2021-2026) & ($ million)
Table 17. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
Table 18. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution and Sales Area
Table 38. Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered
Table 39. Swine Mycoplasma Hyopneumoniae Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Swine Mycoplasma Hyopneumoniae Vaccine
Table 69. Key Market Challenges & Risks of Swine Mycoplasma Hyopneumoniae Vaccine
Table 70. Key Industry Trends of Swine Mycoplasma Hyopneumoniae Vaccine
Table 71. Swine Mycoplasma Hyopneumoniae Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Swine Mycoplasma Hyopneumoniae Vaccine Distributors List
Table 74. Swine Mycoplasma Hyopneumoniae Vaccine Customer List
Table 75. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Zoetis Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 91. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Zoetis Main Business
Table 93. Zoetis Latest Developments
Table 94. Boehringer Ingelheim Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 96. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Boehringer Ingelheim Main Business
Table 98. Boehringer Ingelheim Latest Developments
Table 99. Merck Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 101. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Merck Animal Health Main Business
Table 103. Merck Animal Health Latest Developments
Table 104. Ceva Sant? Animale Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 106. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Ceva Sant? Animale Main Business
Table 108. Ceva Sant? Animale Latest Developments
Table 109. HIPRA Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 111. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. HIPRA Main Business
Table 113. HIPRA Latest Developments
Table 114. Bioveta Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 116. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Bioveta Main Business
Table 118. Bioveta Latest Developments
Table 119. Vaxxinova Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 121. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Vaxxinova Main Business
Table 123. Vaxxinova Latest Developments
Table 124. Nisseiken Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 126. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Nisseiken Main Business
Table 128. Nisseiken Latest Developments
Table 129. Kyoto Biken Laboratories Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 131. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Kyoto Biken Laboratories Main Business
Table 133. Kyoto Biken Laboratories Latest Developments
Table 134. Pulike Biological Engineering Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 136. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Pulike Biological Engineering Main Business
Table 138. Pulike Biological Engineering Latest Developments
Table 139. Wuhan Keqian Biology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 141. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Wuhan Keqian Biology Main Business
Table 143. Wuhan Keqian Biology Latest Developments
Table 144. Qilu Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 146. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Qilu Animal Health Main Business
Table 148. Qilu Animal Health Latest Developments
Table 149. Huapai Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 151. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Huapai Biotechnology Main Business
Table 153. Huapai Biotechnology Latest Developments
Table 154. TianKang Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 156. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. TianKang Pharmaceutical Main Business
Table 158. TianKang Pharmaceutical Latest Developments
Table 159. Jinyu Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 160. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 161. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. Jinyu Bio-technology Main Business
Table 163. Jinyu Bio-technology Latest Developments
Table 164. Zhaofenghua Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 165. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 166. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Zhaofenghua Bio-technology Main Business
Table 168. Zhaofenghua Bio-technology Latest Developments
Table 169. Yunnan Biopharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 170. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 171. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Yunnan Biopharmaceutical Main Business
Table 173. Yunnan Biopharmaceutical Latest Developments
Table 174. Yangzhou Uni-Bio Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 175. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 176. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Yangzhou Uni-Bio Pharmaceutical Main Business
Table 178. Yangzhou Uni-Bio Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 2. Swine Mycoplasma Hyopneumoniae Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inactivated Vaccine
Figure 12. Product Picture of Live Attenuated Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type in 2026
Figure 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Single Vaccine
Figure 17. Product Picture of Dual Vaccine
Figure 18. Product Picture of Others
Figure 19. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency in 2026
Figure 20. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Large-scale Pig Farming Groups
Figure 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Breeding Pig Farms
Figure 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)
Figure 30. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Veterinary Service Providers
Figure 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Veterinary Service Providers (2021-2026) & (K Dose)
Figure 32. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Others
Figure 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2025)
Figure 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025
Figure 36. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company in 2025
Figure 38. Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 88. Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 2. Swine Mycoplasma Hyopneumoniae Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inactivated Vaccine
Figure 12. Product Picture of Live Attenuated Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type in 2026
Figure 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Single Vaccine
Figure 17. Product Picture of Dual Vaccine
Figure 18. Product Picture of Others
Figure 19. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency in 2026
Figure 20. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Large-scale Pig Farming Groups
Figure 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Breeding Pig Farms
Figure 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)
Figure 30. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Veterinary Service Providers
Figure 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Veterinary Service Providers (2021-2026) & (K Dose)
Figure 32. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Others
Figure 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2025)
Figure 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025
Figure 36. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company in 2025
Figure 38. Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 88. Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Application (2027-2032)
